The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.

• Status: Not yet recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Interstitial Lung Disease (ILD) is a is a lung disorder which makes breathing more difficult. During exercise, patients with ILD are not efficient breathers and this leads to serious breathing difficulties, which often causes these patients to stop exercise at low intensities. The investigators think that these patients with ILD have problems exchanging fresh gas (i.e., oxygen) into the blood stream because of poor lung blood vessel function. The investigators will test whether inhaled medications, specifically nitric oxide, can improve lung blood vessel function and decrease breathing difficulties during exercise. With this research, the investigators will understand more about breathing efficiency and lung blood vessel function in mild ILD patients, and find out whether improving lung blood vessel function helps ILD patients breathe easier and exercise longer. Understanding the reasons behind the feeling of difficult breathing may lead to more effective therapy and improved quality of life in ILD patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alberta
• Treatments: Nitric Oxide

Criteria

Inclusion Criteria:

• ILD participants free of any significant cardiovascular, metabolic or neuromuscular disease. Specific criteria are:

• Established physician diagnosis of ILD

• Forced vital capacity 50-80 % predicted

• Diffusing capacity for carbon monoxide 35-60 % predicted

• Able to complete a 6-minute walk test

• Participants will range from 18-85 years old.

• There are no restrictions on pulmonary medications, however, participants will be asked to withdraw from long-acting beta agonists 48 hours prior to trials.

Exclusion Criteria:

• Participants with current or previous history of myocardial infarction or angina pectoris will be excluded.

• Participants with a lowest arterial oxygen saturation < 84% during the initial CPET (day 1) on room air will be excluded.

• Patient receiving treatment for isosorbide mononitrate or pulmonary arterial hypertension (PAH) medications will be excluded.